House Oversight Committee plans to grill more companies on pricing later this year, but rushed rollout of reports from a long-running investigation, combined with competing higher profile news events, seemed to dampen the blow of the latest drug pricing scrutiny. Democrats failed to offer any new, unified solutions for their grievances with industry, while Republicans largely rushed to pharma’s defense.
Novartis US President Thomas Kendris, Amgen CEO Robert Bradway, and Mallinckrodt CEO Mark Trudeau didn't sit at the witness table but testified remotely during the US House Oversight Committee's second day of hearings on Rx pricing on 1 October 2020. • Source: photo illustration from committee feed and company photos
The evening before three drug company executives were set to testify at day two of the House Oversight Committee hearing on pharmaceutical pricing practices 1 October, Democrats were still finishing reports on the companies’ practices. That appeared to be just one of a handful of factors that may have contributed to the committee’s inability to create the mega-attention-grabbing moments that have occurred with past scrutiny of top industry brass like the infamous Oversight Committee Hearings with Martin Shkreli or Mylan Pharmaceuticals Inc. CEO Heather Bresch on EpiPen.
The spotlight on the committee was also diluted by other timing factors. The two-day event kicked off 30 September, when...
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
Doctors are increasingly falling victim to financial scams due to their high incomes, busy schedules, and trust in professional networks. Recognizing the tactics scammers use and the reasons behind physicians’ susceptibility is essential for protecting medical professionals.
Senate HELP Committee chair Sanders trying to broker a deal between Novo Nordisk and the major pharmacy benefit managers that will lead to lower list prices.
Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.
An effort to change the US Food and Drug Administration’s conclusion that its obesity treatment candidate retatrutide is a drug and not a biologic could give the product more time with unrestricted pricing in Medicare, among other benefits.
Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.
The UK regulator approved 16 medicines containing a new active substance in the first half of this year, while the European Commission issued marketing authorizations for 20 NAS-containing drugs.
